Rigel Pharma (RIGL) Reports In-Line Q4 EPS

Rigel Pharma (NASDAQ: RIGL) reported Q4 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $8.9 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• UBS Starts Zhejiang Yinlun Machinery (002126:CH) at Buy
• Canaccord Downgrades Mayne Pharma Group Ltd. (MYX:AU) (MAYNF) to Spec. Buy